JPRN-UMIN000042254招募中未知
Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases in single center cohort study - Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have been treated with nintedanib 2) Patients requiring treatment with anticoagulants and high-dose antiplatelet drugs 3) Patients with a history of acute exacerbations within 6 months 4) Complications of poor control 5) Patients who cannot perform respiratory function test 6) Pregnant patients 7) Other patients who the doctor in charge deems inappropriate for safe administration
研究者
相似试验
招募中
不适用
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational studyProgressive fibrosing interstitial lung diseaseJPRN-UMIN000041380Department of Respiratory Medicine, Juntendo University Hospital300
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60
招募中
不适用
Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)Idiopathic pleuroparenchymal fibroelastosisJPRN-UMIN000042946Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University10
尚未招募
不适用
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patientsDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000615Seoul National University Hospital114
已完成
1 期
Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.advanced colorectal cancerJPRN-UMIN000017114ational Cancer Center55